Skip to main content
. 2022 Jun 28;41(3):541–554. doi: 10.1200/JCO.21.02698

FIG 1.

FIG 1.

Study flow. 1L, first-line; 2L, second-line; ASCT, autologous stem-cell transplant; BR, bendamustine plus rituximab; MCL, mantle cell lymphoma; MR, maintenance rituximab; Obi, obinutuzumab; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SCT, stem-cell transplant.